(NASDAQ: RZLT) Rezolute's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 56.38%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 9.68%.
Rezolute's revenue in 2025 is $0.On average, 3 Wall Street analysts forecast RZLT's revenue for 2027 to be $2,037,070,155, with the lowest RZLT revenue forecast at $324,118,215, and the highest RZLT revenue forecast at $3,228,354,255. On average, 3 Wall Street analysts forecast RZLT's revenue for 2028 to be $9,288,509,686, with the lowest RZLT revenue forecast at $4,717,245,581, and the highest RZLT revenue forecast at $14,143,184,811.
In 2029, RZLT is forecast to generate $19,697,921,073 in revenue, with the lowest revenue forecast at $14,283,436,492 and the highest revenue forecast at $29,522,978,960.